192 related articles for article (PubMed ID: 20843055)
1. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.
Liu S; Bolger JK; Kirkland LO; Premnath PN; McInnes C
ACS Chem Biol; 2010 Dec; 5(12):1169-82. PubMed ID: 20843055
[TBL] [Abstract][Full Text] [Related]
2. Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein.
Ou L; Ferreira AM; Otieno S; Xiao L; Bashford D; Kriwacki RW
J Biol Chem; 2011 Aug; 286(34):30142-51. PubMed ID: 21715330
[TBL] [Abstract][Full Text] [Related]
3. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the modulation of CDK-dependent/independent activity of cyclin D1.
Ferrer JL; Dupuy J; Borel F; Jacquamet L; Noel JP; Dulic V
Cell Cycle; 2006 Dec; 5(23):2760-8. PubMed ID: 17172845
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4.
Larrea MD; Liang J; Da Silva T; Hong F; Shao SH; Han K; Dumont D; Slingerland JM
Mol Cell Biol; 2008 Oct; 28(20):6462-72. PubMed ID: 18710949
[TBL] [Abstract][Full Text] [Related]
6. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Guiley KZ; Stevenson JW; Lou K; Barkovich KJ; Kumarasamy V; Wijeratne TU; Bunch KL; Tripathi S; Knudsen ES; Witkiewicz AK; Shokat KM; Rubin SM
Science; 2019 Dec; 366(6471):. PubMed ID: 31831640
[TBL] [Abstract][Full Text] [Related]
7. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
8. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Zheleva DI; McInnes C; Gavine AL; Zhelev NZ; Fischer PM; Lane DP
J Pept Res; 2002 Nov; 60(5):257-70. PubMed ID: 12383116
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of human CDK4 in complex with a D-type cyclin.
Day PJ; Cleasby A; Tickle IJ; O'Reilly M; Coyle JE; Holding FP; McMenamin RL; Yon J; Chopra R; Lengauer C; Jhoti H
Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4166-70. PubMed ID: 19237565
[TBL] [Abstract][Full Text] [Related]
10. A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein.
Pan W; Cox S; Hoess RH; Grafström RH
Cancer Res; 2001 Apr; 61(7):2885-91. PubMed ID: 11306463
[TBL] [Abstract][Full Text] [Related]
11. New functional activities for the p21 family of CDK inhibitors.
LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
[TBL] [Abstract][Full Text] [Related]
12. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
13. Regulation of G(1) cyclin-dependent kinases in the liver: role of nuclear localization and p27 sequestration.
Albrecht JH; Rieland BM; Nelsen CJ; Ahonen CL
Am J Physiol; 1999 Dec; 277(6):G1207-16. PubMed ID: 10600818
[TBL] [Abstract][Full Text] [Related]
14. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4.
Leng X; Noble M; Adams PD; Qin J; Harper JW
Mol Cell Biol; 2002 Apr; 22(7):2242-54. PubMed ID: 11884610
[TBL] [Abstract][Full Text] [Related]
15. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
[TBL] [Abstract][Full Text] [Related]
16. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
18. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
Ahamed S; Foster JS; Bukovsky A; Diehl JA; Wimalasena J
Mol Carcinog; 2002 May; 34(1):45-58. PubMed ID: 12112322
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2.
Musgrove EA; Hunter LJ; Lee CS; Swarbrick A; Hui R; Sutherland RL
J Biol Chem; 2001 Dec; 276(50):47675-83. PubMed ID: 11590147
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of cyclin-dependent kinase inactivation by progestins.
Musgrove EA; Swarbrick A; Lee CS; Cornish AL; Sutherland RL
Mol Cell Biol; 1998 Apr; 18(4):1812-25. PubMed ID: 9528753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
